SCHEMBL16626646

SCHEMBL16626646

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Cc3ccc(Cl)cc3C(F)(F)F)ccc12

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.39
DDR1 Q08345 2/20 0.38
RORC P51449 3/20 0.37
CCR2 P41597 2/20 0.36
IDE P14735 1/20 0.36
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
P2RX7 Q99572 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619388 0.99 HTR6 (0.39) HTR6DDR1RORCCCR2IDE
SCHEMBL17971578 0.89 HTR6 (0.41) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16618903 0.88 HTR6 (0.40) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626751 0.88 CYP3A4 (0.37) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16618893 0.87 CYP3A4 (0.37) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626681 0.85 HTR6 (0.38) HTR6CCR2IDE
Hydrochloric Acid SCHEMBL16618776 0.85 HTR6 (0.38) HTR6CCR2IDE
SCHEMBL17971579 0.84 SLC6A2 (0.38) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16618994 0.83 SLC6A2 (0.37) HTR6IDEPDE4APDE4BPDE4C
SCHEMBL16626647 0.83 NAMPT (0.39) HTR6IDEPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885DDR1 4292/4885RORC 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.